U.S. markets closed

Cencora, Inc. (COR)

NYSE - NYSE Delayed Price. Currency in USD
234.00-1.64 (-0.70%)
At close: 04:00PM EDT
234.00 0.00 (0.00%)
After hours: 04:41PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close235.64
Bid232.19 x 900
Ask237.90 x 800
Day's Range233.10 - 236.24
52 Week Range163.37 - 246.75
Avg. Volume1,243,088
Market Cap46.629B
Beta (5Y Monthly)0.47
PE Ratio (TTM)25.52
EPS (TTM)9.17
Earnings DateMay 01, 2024
Forward Dividend & Yield2.04 (0.87%)
Ex-Dividend DateFeb 08, 2024
1y Target Est254.14
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for COR

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Cencora, Inc.
    Analyst Report: Cencora IncHeadquartered in Conshohocken, Pennsylvania, Cencora, formerly AmerisourceBergen, is one of the nation's largest pharmaceutical distributors. The company distributes brand-name and generic pharmaceuticals, over-the-counter (OTC) healthcare products, and home healthcare supplies and equipment to healthcare providers throughout the U.S. It also provides pharmaceuticals and pharmacy services to patients requiring specialty drugs such as immunology and oncology treatments. Cencora has international operations through its World Courier logistics business and assets acquired from Alliance Healthcare and PharmaLex.
    Fair Value
    Economic Moat
    10 days agoArgus Research
View more